Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma.
作者信息
Bolen Christopher R, Mattiello Federico, Herold Michael, Hiddemann Wolfgang, Huet Sarah, Klapper Wolfram, Marcus Robert, Mir Farheen, Salles Gilles, Weigert Oliver, Nielsen Tina, Oestergaard Mikkel Z, Venstrom Jeffrey M
机构信息
Bioinformatics & Computational Biology, Genentech Inc., South San Francisco, CA.
Pharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
出版信息
Blood. 2021 May 13;137(19):2704-2707. doi: 10.1182/blood.2020008119.
Abstract
摘要
相似文献
1
Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma.初发性滤泡性淋巴瘤中预后基因表达特征的治疗依赖性
Blood. 2021 May 13;137(19):2704-2707. doi: 10.1182/blood.2020008119.
2
Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.一线采用苯达莫司汀-利妥昔单抗治疗滤泡淋巴瘤后维持利妥昔单抗或观察。
Br J Haematol. 2019 Feb;184(4):524-535. doi: 10.1111/bjh.15720. Epub 2018 Dec 21.
3
Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy.一线免疫化疗滤泡性淋巴瘤患者循环 Bcl-2/IgH 水平的预后价值。
Blood. 2015 Sep 17;126(12):1407-14. doi: 10.1182/blood-2015-03-630012. Epub 2015 Aug 3.
4
Pembrolizumab and lenalidomide induced remission in refractory double-hit lymphoma.帕博利珠单抗和来那度胺诱导难治性双打击淋巴瘤缓解。
Ann Hematol. 2016 Oct;95(11):1917-8. doi: 10.1007/s00277-016-2771-2. Epub 2016 Jul 30.
5
Progressive multifocal leukoencephalopathy during rituximab maintenance after rituximab and bendamustine treatment for relapsed follicular lymphoma.利妥昔单抗和苯达莫司汀治疗复发滤泡性淋巴瘤后利妥昔单抗维持治疗期间发生的进行性多灶性白质脑病。
Ann Hematol. 2020 Sep;99(9):2191-2192. doi: 10.1007/s00277-020-04143-x. Epub 2020 Jun 17.
6
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.在 GALLIUM 研究中，奥滨尤妥珠单抗或利妥昔单抗联合化疗治疗初治滤泡性淋巴瘤：化疗对疗效和安全性的影响。
J Clin Oncol. 2018 Aug 10;36(23):2395-2404. doi: 10.1200/JCO.2017.76.8960. Epub 2018 Jun 1.
7
First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis.初治滤泡性淋巴瘤 3A 级患者采用 R-CHOP 或利妥昔单抗-苯达莫司汀治疗的回顾性分析结果。
Ann Hematol. 2020 Dec;99(12):2821-2829. doi: 10.1007/s00277-020-04171-7. Epub 2020 Jul 30.
8
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.MLH1基因分型可识别出一组无法从多柔比星治疗中获益的滤泡性淋巴瘤患者：FIL-FOLL研究。
Haematologica. 2015 Apr;100(4):517-24. doi: 10.3324/haematol.2014.108183. Epub 2015 Jan 16.
9
Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab.利妥昔单抗治疗后，阿扎胞苷治疗CD20阴性转化型弥漫性大B细胞淋巴瘤可部分恢复CD20蛋白表达及利妥昔单抗敏感性。
Ann Hematol. 2018 Nov;97(11):2253-2255. doi: 10.1007/s00277-018-3354-1. Epub 2018 May 3.
10
Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era.在利妥昔单抗时代，可溶性白细胞介素-2受体水平可预测接受环磷酰胺、多柔比星、长春新碱和泼尼松化疗的滤泡性淋巴瘤患者的生存率。
Leuk Lymphoma. 2014 Jul;55(7):1584-90. doi: 10.3109/10428194.2013.850167. Epub 2014 Feb 4.
引用本文的文献
1
Follicular lymphoma: contemporary clinical management with a focus on recent therapeutic advances.滤泡性淋巴瘤：当代临床管理，重点关注近期治疗进展
Korean J Intern Med. 2025 May;40(3):371-393. doi: 10.3904/kjim.2024.279. Epub 2025 Feb 21.
2
The POD24 challenge: where do we go from here for early progressors?无进展生存期24个月的挑战：对于疾病早期进展者，我们从这里该何去何从？
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):301-309. doi: 10.1182/hematology.2024000662.
3
Identification of genetic subtypes in follicular lymphoma.滤泡性淋巴瘤的基因亚型鉴定。
Blood Cancer J. 2024 Aug 7;14(1):128. doi: 10.1038/s41408-024-01111-w.
4
Recent advances in understanding the biology of follicular lymphoma.滤泡性淋巴瘤生物学认识的最新进展
Int J Hematol. 2025 Mar;121(3):326-330. doi: 10.1007/s12185-024-03764-6. Epub 2024 Mar 27.
5
High hypoxia status in pancreatic cancer is associated with multiple hallmarks of an immunosuppressive tumor microenvironment.胰腺癌中的高缺氧状态与免疫抑制性肿瘤微环境的多个特征有关。
Front Immunol. 2024 Mar 6;15:1360629. doi: 10.3389/fimmu.2024.1360629. eCollection 2024.
6
Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entities.多模态和空间分辨分析鉴定出结内 B 细胞淋巴瘤实体中 T 细胞浸润的不同模式。
Nat Cell Biol. 2024 Mar;26(3):478-489. doi: 10.1038/s41556-024-01358-2. Epub 2024 Feb 20.
7
Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.滤泡性淋巴瘤进展相关突变预示着诊断时预后不良：Alliance A151303 研究。
Blood Adv. 2023 Sep 26;7(18):5524-5539. doi: 10.1182/bloodadvances.2023010779.
8
Long-term follow-up confirms the favourable prognostic impact of high numbers of tumour infiltrating CD3 T-cells in follicular lymphoma patients treated by rituximab-maintenance regimen.长期随访证实，在接受利妥昔单抗维持治疗方案的滤泡性淋巴瘤患者中，大量肿瘤浸润性CD3 T细胞具有良好的预后影响。
Br J Haematol. 2023 Aug;202(3):686-689. doi: 10.1111/bjh.18881. Epub 2023 May 22.
9
Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma.滤泡性淋巴瘤一线化疗免疫治疗期间的中期正电子发射断层扫描
Hemasphere. 2023 Jan 24;7(2):e826. doi: 10.1097/HS9.0000000000000826. eCollection 2023 Feb.
10
Biology of follicular lymphoma: insights and windows of clinical opportunity.滤泡性淋巴瘤的生物学特性：深入了解与临床契机
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):688-694. doi: 10.1182/hematology.2022000361.
本文引用的文献
1
Localized- and advanced-stage follicular lymphomas differ in their gene expression profiles.局部晚期和晚期滤泡性淋巴瘤在基因表达谱上存在差异。
Blood. 2020 Jan 16;135(3):181-190. doi: 10.1182/blood.2019000560.
2
How I treat early-relapsing follicular lymphoma.我如何治疗早期复发滤泡性淋巴瘤。
Blood. 2019 Apr 4;133(14):1540-1547. doi: 10.1182/blood-2018-08-822148. Epub 2019 Jan 30.
3
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.初治滤泡性淋巴瘤采用免疫化疗治疗的简化评分系统。
Blood. 2018 Jul 5;132(1):49-58. doi: 10.1182/blood-2017-11-816405. Epub 2018 Apr 17.
4
A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.基于基因表达谱的滤泡性淋巴瘤患者预后预测评分：三队列回顾性训练和验证分析。
Lancet Oncol. 2018 Apr;19(4):549-561. doi: 10.1016/S1470-2045(18)30102-5. Epub 2018 Feb 20.
5
Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets.突变负荷和效应T细胞基因特征可能区分免疫上不同且临床相关的淋巴瘤亚群。
Blood Adv. 2017 Sep 27;1(22):1884-1890. doi: 10.1182/bloodadvances.2016000786. eCollection 2017 Oct 10.
6
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.奥滨尤妥珠单抗用于滤泡性淋巴瘤的一线治疗。
N Engl J Med. 2017 Oct 5;377(14):1331-1344. doi: 10.1056/NEJMoa1614598.
7
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.在接受一线免疫化疗的滤泡性淋巴瘤患者中，基因突变更新预后风险预测：一项前瞻性临床试验的回顾性分析及基于人群的登记处验证。
Lancet Oncol. 2015 Sep;16(9):1111-1122. doi: 10.1016/S1470-2045(15)00169-2. Epub 2015 Aug 6.
8
The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association.CD163 阳性巨噬细胞对滤泡性淋巴瘤预后的影响：来自加拿大不列颠哥伦比亚癌症署和淋巴瘤研究协会的研究。
Clin Cancer Res. 2015 Aug 1;21(15):3428-35. doi: 10.1158/1078-0432.CCR-14-3253. Epub 2015 Apr 13.
9
Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience.4 个十年期间滤泡性 1-2 级淋巴瘤观察到和相对生存率的改善：斯坦福大学的经验。
Blood. 2013 Aug 8;122(6):981-7. doi: 10.1182/blood-2013-03-491514. Epub 2013 Jun 18.
10
Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.滤泡性淋巴瘤国际预后指数2：由国际滤泡性淋巴瘤预后因素项目制定的滤泡性淋巴瘤新预后指数。
J Clin Oncol. 2009 Sep 20;27(27):4555-62. doi: 10.1200/JCO.2008.21.3991. Epub 2009 Aug 3.
Zotero 插件